FindTrial
Sign In

A retrospective study of fenetyllone based on propensity score matching for the treatment of T2DM-related CKD

A retrospective study of fenetyllone based on propensity score matching for the treatment of T2DM-related CKD

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500102791
Enrollment
Unknown
Registered
2025-05-20
Start date
2024-06-01
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

T2DM-related CKD

Interventions

SoC + Finerenone group:None
standard of care group:None

Sponsors

Fujian Medical University Affiliated Union Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) T2DM-associated CKD patients; (2) age >=18 years; (3) serum potassium <=5.5 mmol/L; and (4) patients with good adherence to continuous finerenone therapy for 4 months or more as prescribed by their physician.

Exclusion criteria

Exclusion criteria: (1) chronic kidney disease not associated with T2DM; (2) patients with a combination of other malignancies, severe organic pathology, or pregnancy; (3) fewer than two clinical test results; (4) patients scheduled for dialysis or kidney transplantation; and (5) patients with incomplete medical history or lost to follow-up.

Design outcomes

Primary

MeasureTime frame
Estimated glomerular filtration rate;—

Secondary

MeasureTime frame
Serum potassium;Urinary microalbumin creatinine ratio;Hospitalization costs;—

Countries

China

Contacts

Public ContactLiu Libin

Fujian Medical University Affiliated Union Hospital

libinliu@fjmu.edu.cn+86 133 6591 0510

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026